These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 22236202)
1. Thymidine kinase assay in canine lymphoma. Elliott JW; Cripps P; Blackwood L Vet Comp Oncol; 2013 Mar; 11(1):1-13. PubMed ID: 22236202 [TBL] [Abstract][Full Text] [Related]
2. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs. von Euler HP; Ohrvik AB; Eriksson SK Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350 [TBL] [Abstract][Full Text] [Related]
3. A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma. Sharif H; von Euler H; Westberg S; He E; Wang L; Eriksson S Vet J; 2012 Oct; 194(1):40-7. PubMed ID: 22516918 [TBL] [Abstract][Full Text] [Related]
4. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity--evaluation of a new, fully automated non-radiometric assay. Von Euler HP; Rivera P; Aronsson AC; Bengtsson C; Hansson LO; Eriksson SK Int J Oncol; 2009 Feb; 34(2):505-10. PubMed ID: 19148486 [TBL] [Abstract][Full Text] [Related]
5. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. Nakamura N; Momoi Y; Watari T; Yoshino T; Tsujimoto H; Hasegawa A J Vet Med Sci; 1997 Oct; 59(10):957-60. PubMed ID: 9362053 [TBL] [Abstract][Full Text] [Related]
6. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. von Euler H; Einarsson R; Olsson U; Lagerstedt AS; Eriksson S J Vet Intern Med; 2004; 18(5):696-702. PubMed ID: 15515587 [TBL] [Abstract][Full Text] [Related]
7. Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*. Thamm DH; Kamstock DA; Sharp CR; Johnson SI; Mazzaferro E; Herold LV; Barnes SM; Winkler K; Selting KA Vet Comp Oncol; 2012 Dec; 10(4):292-302. PubMed ID: 22236280 [TBL] [Abstract][Full Text] [Related]
8. A method to distinguish between the de novo induction of thymidine kinase mutants and the selection of pre-existing thymidine kinase mutants in the mouse lymphoma assay. Wang J; Heflich RH; Moore MM Mutat Res; 2007 Jan; 626(1-2):185-90. PubMed ID: 17055776 [TBL] [Abstract][Full Text] [Related]
9. Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs. Wolfesberger B; Tonar Z; Fuchs-Baumgartinger A; Walter I; Skalicky M; Witter K; Thalhammer JG; Pagitz M; Kleiter M Res Vet Sci; 2012 Jun; 92(3):444-50. PubMed ID: 21596405 [TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma. Marconato L; Crispino G; Finotello R; Mazzotti S; Zini E J Am Vet Med Assoc; 2010 May; 236(9):969-74. PubMed ID: 20433396 [TBL] [Abstract][Full Text] [Related]
11. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker. Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656 [TBL] [Abstract][Full Text] [Related]
12. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. Madewell BR J Vet Intern Med; 2004; 18(5):595-6. PubMed ID: 15515571 [TBL] [Abstract][Full Text] [Related]
13. Microvessel density in normal lymph nodes and lymphomas of dogs and their correlation with vascular endothelial growth factor expression. Wolfesberger B; Tonar Z; Witter K; Guija de Arespacohaga A; Skalicky M; Walter I; Thalhammer JG; Egger GF Res Vet Sci; 2008 Aug; 85(1):56-61. PubMed ID: 17888471 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma. Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577 [TBL] [Abstract][Full Text] [Related]
16. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients. Bogni A; Cortinois A; Grasselli G; Seregni E; Crippa F; Castellani MR; Bombardieri E J Biol Regul Homeost Agents; 1994; 8(4):121-5. PubMed ID: 7660854 [TBL] [Abstract][Full Text] [Related]
17. Expression of the high mobility group A1 (HMGA1) and A2 (HMGA2) genes in canine lymphoma: analysis of 23 cases and comparison to control cases. Joetzke AE; Sterenczak KA; Eberle N; Wagner S; Soller JT; Nolte I; Bullerdiek J; Murua Escobar H; Simon D Vet Comp Oncol; 2010 Jun; 8(2):87-95. PubMed ID: 20579321 [TBL] [Abstract][Full Text] [Related]
18. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837 [TBL] [Abstract][Full Text] [Related]
19. High-mobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy. Meyer A; Eberle N; Bullerdiek J; Nolte I; Simon D Vet Comp Oncol; 2010 Jun; 8(2):127-37. PubMed ID: 20579326 [TBL] [Abstract][Full Text] [Related]
20. Substrate specificity of feline and canine herpesvirus thymidine kinase. Solaroli N; Johansson M; Persoons L; Balzarini J; Karlsson A Antiviral Res; 2008 Aug; 79(2):128-32. PubMed ID: 18455811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]